Blood pressure, echocardiography, and aortic and peripheral arterial pulse-wave velocity were studied in 40 hypertensive patients on long-term hemodialysis during a 24-week administration of nitrendipine (1,4-dihydro-2,6-dimethyl-4-[m-nitrophenyl] -3,5-pyridine-dicarboxylic acid ethyl methylester) monotherapy. In a double-blind placebo-randomized study, nitrendipine effectively lowered the blood pressure (p<0.001) before hemodialysis without causing postdialysis hypotension. The antihypertensive effect of nitrendipine was greater in patients with significant salt and water retention, as indicated by interdialytic body weight gain (ABW), that is, a significant correlation was observed between ABW and the decrease in blood pressure (r=0.72; p<0.001 
Blood pressure, echocardiography, and aortic and peripheral arterial pulse-wave velocity were studied in 40 hypertensive patients on long-term hemodialysis during a 24-week administration of nitrendipine (1,4-dihydro-2,6-dimethyl-4-[m-nitrophenyl] -3,5-pyridine-dicarboxylic acid ethyl methylester) monotherapy. In a double-blind placebo-randomized study, nitrendipine effectively lowered the blood pressure (p<0.001) before hemodialysis without causing postdialysis hypotension. The antihypertensive effect of nitrendipine was greater in patients with significant salt and water retention, as indicated by interdialytic body weight gain (ABW), that is, a significant correlation was observed between ABW and the decrease in blood pressure (r=0.72; p<0.001). The antihypertensive effect was not related to age, pretreatment plasma renin activity, or serum-ionized calcium concentration. After nitrendipine, a time-related decrease in aortic (p<0.005) and femoral (p<0.05) pulse-wave velocity was observed with a significant time-treatment interaction (p<0.01). Nitrendipine treatment did not influence left ventricular mass (which was positively correlated with ABW; p<0.01) but was associated with an increase in the left ventricular ejection fraction. The increase in ejection fraction was correlated with changes in aortic pulse-wave velocity (r=0.548; p<0.02) but not with changes in blood pressure (r=0.352; p =0. 19) or ABW. This study shows that in patients on hemodialysis, 1) the antihypertensive effect of nitrendipine is related to sodium and water retention, 2) the long-term administration of nitrendipine increases aortic distensibility but does not influence left ventricular hypertrophy, and 3) the increase in aortic distensibility is associated with an improvement in left ventricular function. (Circulation 1990; 82:105-113) Several experimental and clinical studies1-4 have indicated that an inverse relation exists l, between the sodium status and the antihypertensive effects of dihydropyridine derivatives and other calcium channel blocking drugs. After experimentally induced hypertension, calcium channel blocking agents lower the arterial pressure to a greater extent in deoxycorticosterone acetate-saline loaded, low-renin hypertensive rats than in Goldblatt rats.12 Consistent with this observation, the antihypertensive effects of verapamil and nifedipine were enhanced in low-renin human hypertension,35 and the hypotensive effects of nifedipine were greater in patients with a high sodium intake. 4 Hypertension is frequently observed in patients with end-stage renal failure (ESRF),6 and is an important factor in accelerated arterial degeneration and the increased risk of cardiovascular failure in these patients. 78 The major pathogenic factors favoring hypertension in ESRF are increased body sodium and water retention.9 Efficacy of nifedipine in acute10 or short-term treatment11 of hypertension in hemodialyzed patients has been demonstrated, and Salvetti et al12 have shown that acute hypotensive response to nifedipine is greater during overhydration (before dialysis) than during volume depletion (after dialysis).
Sodium and water retention in ESRF are not only associated with an increase in blood pressure but might also directly influence cardiac and vascular function. We hypothesized that using calcium channel blockers to treat these conditions would not only ensure long-term control of arterial pressure but also elicit cardiovascular alterations independent of the antihypertensive effects. We conducted a doubleblind placebo-randomized clinical trial with nitrendipine (1,4-dihydro-2,6-dimethyl-4-[m-nitrophenyl]-3,5-pyridine-dicarboxylic acid ethyl methylester), a new dihydropyridine derivative that exerts its antihypertensive action for 24 hours after a single oral dose,'3 that has unaltered pharmacokinetics despite impaired renal function,'4 and that, in an uncontrolled study, decreased blood pressure in dialysis patients.15
Methods

Study Population
This study involved patients with ESRF treated by hemodialysis for at least 6 months and median predialysis blood pressure (BP) greater than 160/95 mm Hg. Admissibility criteria included absence of acute myocardial infarction, valvular heart disease, peripheral vascular disease, cerebral vascular disease, and decompensated heart failure. One hundred twenty-eight patients treated in the same dialysis unit were screened, and 46 hypertensive subjects of either sex were recruited. Twenty-seven of the hypertensive subjects were already on antihypertensive therapy. In these patients, the current antihypertensive medications were progressively reduced over measured between feet of flow waves recorded at the different points, averaged over at least 10 beats, and designated as pulse transit time (t). The distance traveled by the pulse was measured over the surface of the body with a tape measure, as distance between sites (D). Arterial PWV was calculated over the three arterial segments as PWV equals D divided by t. '8 For the measurements of PWV between the base of the neck and the femoral artery, the distance from the suprasternal notch to the carotid was subtracted from the total distance to take into consideration the pulse traveling in the opposite direction, the PWV being designated as aortic PWV. The PWV between femoral and posterior tibial arteries was designated as femoral PWV, and that between brachial and radial arteries was designated as brachial PWV.18 As previously described,16 the individual day-to-day variability was for aortic PWV (5.3±3.6%), femoral PWV (5.5±4%), and brachial PWV (7.2±4%). 22 The magnitude of patient salt and water retention was measured as the difference between the dry weight achieved during the preceding dialysis and the patient's weight before dialysis on the day of the measurement. Changes in body weight (lABW) were expressed in kilograms (kg) or in kilograms per squared meter (kg/M2) because ABW was correlated with body surface area (r=0.813, p<0.001).
Laboratory Evaluation
Blood samples were obtained after a 12-hour fast from patients in a supine position (after 30 minutes of rest) just before the dialysis. All samples were assayed by standard methods on an autoanalyzer (model RA 1000, Technicon, Dumont, France). Ionized calcium was measured in serum samples dxawn and processed anaerobically by using an ion-specific calcium electrode (ICA2-Radiometer, Copenhagen, Denmark). The normal value in our laboratory for sex-matched and age-matched controls is 1.25±0.03 mmol/l. Plasma renin activity was determined by radioimmunoassay using specific antisera.
Statistical Methods and Analysis
The analysis of efficacy was performed between day zero and the 16th week. For the quantitative variables, the results are given as mean ±SD. The homogeneity of the randomized groups at day zero was determined by means of a Student's t test on independent series. Repeated measure analysis of variance for a threefactorial design (patient-time-treatment) was performed. A Newman-Keuls test was performed in the case of significant interaction. Univariate and multivariate correlations were performed using the least-squares method. At the 24th week, due to the lack of a control group, the results of the group of patients taking nitrendipine are only descriptive.
Results
Subjects
One patient of the group taking placebo dropped out of the study after 4 weeks for DBP persistently higher than 114 mm Hg. Therefore, the analysis was not observed in any patient. Heart rate increased during standing both before and after dialysis.
Effects ofnitrendipine. Table 2 shows the changes in the prehemodialysis and posthemodialysis BP during the study. In the group of patients taking nitrendipine, the predialysis BP decreased in supine as well as standing positions; the effect of treatment was significant (p<0.001) as was the time-treatment interaction (p<0.001). To the difference with the baseline period, the predialysis BP was no more correlated with ABW. Postdialysis BP was not significantly affected by nitrendipine. Hemodialysis ultrafiltration did not induce a decrease in SBP but, to the contrary, induced an increase in DBP (p<0.02).
Prehemodialysis BP remained unchanged in the group of patients taking placebo. In the group taking placebo, hemodialysis continued to be associated with a decrease in SBP (p<0.02).
Nitrendipine did not influence the heart rate in the supine position and did not interfere with the heart rate acceleration on standing.
The ankle SBP decreased from 208±25 mm Hg at baseline to 180+42 mm Hg (p<0.001) after 16 weeks of treatment with nitrendipine. In the group of patients taking placebo, the ankle SBP remained unchanged (213+23 at baseline vs. 212±22 mm Hg at 16 weeks). Ankle/arm SBP ratio remained unchanged in the two groups (Table 4) . Figure  1 ). Because we also observed a positive correlation between the baseline SBP and ABW, a multivariate regression analysis was performed to separate the predictive roles of baseline SBP and ABW on antihypertensive response. As indicated in Table 3 , the ABW was the independent determinant of the effect of nitrendipine. The changes in predialysis DBP were correlated to baseline ABW (r=0.515, p<0.05).
Pulse Wave Velocity and Aortic Diameter
Baseline arterial PWVs were similar in the two groups. In the overall population, the aortic PWV is correlated with patient age (r=0.54, p<0.001) and baseline SBP (r=0.58, p<0.001). The results shown in Table 4 concern data from the 18 (Figure 2 ). In the group taking nitrendipine, the aortic PWV continued to decrease between the 16th and the 24th weeks (p<O.O1), whereas BP did not change significantly (p=0.55). Aortic diameters were not modified after active treatment (Table 4 ). Aortic and iliofemoral calcifications were present in 11 (55%) patients in the group taking nitrendipine and in 13 subjects in the group of patients taking placebo. Brachial artery calcifications were observed in four patients of each group.
Echocardiographic Measurements
The baseline echocardiographic parameters were similar in the two groups. In the overall population of 39 subjects, the left ventricular mass (LVM) at baseline was not correlated to SBP (r=0.152) or DBP (r=0.24), but a significant correlation was observed with ABW (r=0.496,p<0.01) (Figure 3) . LVM was not influenced by nitrendipine. The baseline ventricular EF was 58.5 + 12% in the group of patients taking nitrendipine compared with 65.3+±8.7% in the group of patients taking placebo (p=0.06). In the group taking nitrendipine, the EF increased to 63±9.4% at 16 weeks and 63.4±8.9% at 24 weeks with a significant time-related effect (p<0.O1). In patients receiving placebo, the ventricular EF decreased nonsignificantly to 62.1±8.6% at 16 weeks (p=0.06). Because the EFs of the two groups were comparable at 16 weeks, the time-treatment interaction was not significant. The changes in EF observed in the group taking nitrendipine were correlated with changes in aortic PWV (r=-0.548, p<0.02) but not with changes in BP (r=0.352, p=0.19) (Figure 4 ).
Body Weight and Blood Chemistry
No significant changes in body weight and ABW occurred during the study, and at 16 weeks, the ABW was 2.47±0.71 kg in the group of patients taking placebo compared with 2.48±0.75 kg in the group taking nitrendipine. Plasma renin activity was not influenced by nitrendipine (49.8±20.1 at baseline and 54±25.1 pg/ml/hr at 16 weeks in the active-treatment group of patients, and 50.1±24.4 at baseline and 44±22.8 pg/ml/hr at 16 weeks in the group of patients taking placebo). Baseline predialysis plasma-ionized calcium was 1.22±0.07 mmol/l in the group of patients taking placebo, similar to values observed in the group taking nitrendipine, that is, 1.21±0.07 mmol/l. Predialysis ionized calcium did not change significantly during the study. Hemodialysis itself induced a hypercalcemia, and baseline postdialysis ionized calcium was 1.41+0.06 mmol/l in the group taking placebo and 1.43±0.07 mmol/l in the group taking nitrendipine (NS). Hemodialysis-induced hypercalcemia was not modified during the study. Hemodialysis-induced changes in blood pressure were not correlated with dialysis-induced variations in the ionized calcium.
Discussion
The present study demonstrates that a long-term antihypertensive effect can be achieved in patients on maintenance hemodialysis by using nitrendipine alone. The decrease in BP was maintained without changes in heart rate, as previously observed in uremic subjects, as well as in essential hypertensive patients with normal renal function.15,23-25 The principal results of the study concern the determination of the antihypertensive effect of nitrendipine and the cardiovascular consequences of nitrendipine treatment. Indeed, several studies in essential hypertensive patients have shown that age, baseline BP, renin, and serum-ionized calcium are indicative of the therapeutic effect of calcium antagonists.5,26 In contrast, in patients with ESRF, we did not observe any relation between these factors and an antihypertensive effect. The role of terminal uremia is not necessarily responsible because a similar absence of relations between age, renin activity, or both and the antihypertensive effect of nitrendipine was also observed in essential hypertensives with normal renal function.2325 Body fluid volume status of the patients was appreciated on the basis of interdialytic body weight gain. In general, it is impossible to determine the ideal body weight for a dialysis patient; the dry weight after hemodialysis might be the patient's optimal weight or it might be a relative hypovolemic state. It is, therefore, possible that the weight gain between dialyses does not represent a volume overload in the absolute terms. Nevertheless, from the point of view of BP regulation in uremic patients, the interdialytic ABW correlates directly with predialysis BP, and the decrease in BP induced by hemodialysis correlates with body weight changes achieved by ultrafiltration during dialysis. Therefore, the interdialytic ABW changes represent a volume overload (relative or absolute) directly associated with the patient's blood pressure. The patient's volume status was the principal determinant of the antihypertensive effect of nitrendipine. This was suggested by several observations made in the present study. First, a significant correlation was observed between the ABW and the antihypertensive action of nitrendipine (Figure 1 ). Second, a correlation between predialysis BP and ABW was observed in baseline conditions but not after nitrendipine treatment. Third, the antihypertensive effect of the drug was obvious before dialysis but not after dialysis at dry weight. To the contrary, after sodium and water removal during dialysis, the DBP increased in the group of patients taking nitrendipine. PWVV is determined by the elastic modulus of the arterial wall. The elastic modulus of the artery wall increases with circumferential tension, and PWV depends on arterial pressure, that is, the higher the pressure, the faster the speed of wave travel. The pressure dependency of elastic modulus is due to the two-phase content of the arterial wall (elastin and collagen fibers), with stress being distributed between the distensible elastic fibers over the physiological range of arterial pressure and being applied to less extensible collagenous fibers at higher distending pressures.30 Therefore, the changes in PWV could be the passive consequences of the changes in BP, and thus, it is possible that the changes in PWVs observed at 16 weeks were related only to the nitrendipineinduced decrease in BP (Figure 2) . Nevertheless, the continuous decrease in PWV observed at 24 weeks despite a constant BP could indicate a progressive modification of the elastic properties of the arterial walls. Most experimental studies agree that after antihypertensive treatment, the reversal of smooth muscle cell hypertrophy is more rapid and complete than the reversal of collagen deposition, which is incomplete and protracted.31 After 24 weeks on nitrendipine therapy, the aortic PWV of our patients was comparable with values observed in age-matched normal populations.'6 This is more consistent with the smooth muscle cell hypertrophy being the principal alteration responsible for decreased arterial compliance in end-stage renal disease. In opposition to aortic and femoral PWV, brachial PWV did not decrease significantly during treatment with nitrendipine. Such a different response of the various arterial segments could be due to the predilection of degenerative arterial lesions for the aorta and lower limb arteries, whereas the upper limb vessels are usually spared. 32 The vasculature of patients with chronic renal failure is a primary target for arterial degenerative disorders, including atherosclerosis and extensive arterial calcification.33,34 Aortic and iliofemoral calcifications were present in 55% of patients receiving nitrendipine. Contrasting with such frequency, brachial artery calcifications were observed in only four (20%) patients. An alternative explanation for the absence of changes in brachial PWV could be a difference in the degree of vasodilation of the peripheral arteries of the limb, with a more or less pronounced pressure-wave reflection and difference in the local pressure gradient. The fact that the BP changes were similar in the upper and lower limbs, whereas the ankle/arm SBP ratio remained constant, does not Figure 3 shows, are correlated to the degree of cardiac hypertrophy. Administration of nitrendipine was associated with an improvement of the EF. The increase in EF was not related to the decrease in BP but to the decrease in aortic PWV (Figure 4 ). Because aortic PWV is directly proportional to aortic characteristic impedance,1718 these results could indicate that increased arterial distensibility has a beneficial effect on cardiac load.
The present study has shown that in patients on hemodialysis for ESRF, nitrendipine administered alone effectively reduced hypertension for periods of up to 24 weeks. Nitrendipine controlled BP in conditions of salt and water retention, and the antihypertensive effect was directly related to patients' volume status, being more pronounced in patients with the highest interdialytic ABW. The long-term administration of nitrendipine resulted in a progressive increase in aortic distensibility, which was associated with an improvement of left ventricular ejection. Contrasting with that antihypertensive effect, nitrendipine treatment was not associated with a reduction of the LVM. The study shows that after treatment with certain calcium antagonists, the cardiac and arterial changes can be dissociated from each other and from the antihypertensive effect. Dissociated responses of the arteries and the heart to arterial pressure changes were observed in essential hypertensive subjects.29 Indeed, Asmar et a129 have shown that structural changes in the vessels have a shorter time constant than changes in the heart. The shorter time constant of vascular changes during antihypertensive therapy could explain the dissociation observed in the present study between the changes in arterial PWV and the nonreversal of cardiac hypertrophy after administration of nitrendipine.
